Mo Dongping, Gu Bing, Gong Xue, Wu Lei, Wang Hong, Jiang Ye, Zhang Bingfeng, Zhang Meijuan, Zhang Yan, Xu Jian, Pan Shiyang
1 Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 National Key Clinical Department of Laboratory Medicine, Nanjing 210029, China.
J Thorac Dis. 2015 Sep;7(9):1570-9. doi: 10.3978/j.issn.2072-1439.2015.09.38.
miR-1290 is a newly discovered microRNA (miRNA), and its role in non-small cell lung cancer (NSCLC) remains unknown. This study aimed to evaluate the expression levels of miR-1290 in NSCLC tissues and serum, and explore its associations with clinicopathological characteristics and prognosis of NSCLC patients.
A total of 33 pairs of tissues and 73 serum samples were obtained from NSCLC patients and expression levels of miR-1290 were detected by specific TaqMan qRT-PCR. The relationship between miR-1290 expression levels in NSCLC tissues and serum and clinicopathological characteristics was estimated respectively. The correlation between serum miR-1290 expression levels and overall survival of NSCLC patients was performed by Kaplan-Meier analysis and Cox proportional hazards model.
We determined that miR-1290 expression levels were increased significantly in NSCLC tissues compared with non-tumor adjacent normal tissues, and higher miR-1290 expression levels were positively correlated with high tumor stage (P=0.004) and positive lymph node metastasis (P=0.013). Compared with benign lung disease and healthy controls, serum levels of NSCLC patients exhibited higher expression of miR-1290. Furthermore, the up-regulation of serum miR-1290 more frequently occurred in NSCLC patients with high TNM stage, positive lymph node metastasis (P=0.022 and P=0.024, respectively). Kaplan-Meier analysis demonstrated that high serum miR-1290 expression levels predicted poor survival (P=0.022). Cox proportional hazards risk analysis indicated that miR-1290 was an independent prognostic factor for NSCLC.
Our study suggests that miR-1290 is overexpressed in NSCLC, and serum miR-1290 may be used as a potential prognostic biomarker for NSCLC.
miR - 1290是一种新发现的微小RNA（miRNA），其在非小细胞肺癌（NSCLC）中的作用尚不清楚。本研究旨在评估miR - 1290在NSCLC组织和血清中的表达水平，并探讨其与NSCLC患者临床病理特征及预后的关系。
收集33对NSCLC患者的组织和73份血清样本，采用特异性TaqMan qRT - PCR检测miR - 1290的表达水平。分别评估NSCLC组织和血清中miR - 1290表达水平与临床病理特征的关系。采用Kaplan - Meier分析和Cox比例风险模型分析血清miR - 1290表达水平与NSCLC患者总生存的相关性。
我们发现，与肿瘤旁正常组织相比，NSCLC组织中miR - 1290表达水平显著升高，且较高的miR - 1290表达水平与高肿瘤分期（P = 0.004）和阳性淋巴结转移（P = 0.013）呈正相关。与良性肺病和健康对照相比，NSCLC患者血清中miR - 1290表达更高。此外，血清miR - 1290上调在TNM分期高、有阳性淋巴结转移的NSCLC患者中更常见（分别为P = 0.022和P = 0.024）。Kaplan - Meier分析表明，血清miR - 1290高表达预示生存较差（P = 0.022）。Cox比例风险分析表明，miR - 1290是NSCLC的独立预后因素。
我们的研究表明，miR - 1290在NSCLC中过表达，血清miR - 1290可能作为NSCLC潜在的预后生物标志物。
